Monthly Archives: September 2019

5 Things to Know about Lung Cancer Treatment

Getting a lung cancer diagnosis can be a paralyzing moment. Genprex outlines five things you should know about lung cancer treatment.

Read More

A Deeper Dive into the Nature Research Scientific Report on TUSC2 and Triple-Negative Breast Cancer

Genprex takes a deeper dive into the data of the study to provide analysis and a better understanding of what the study found and what it means for TUSC2.

Read More

Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company's webcast presentation.

Read More

Genprex is Defining a New Immunogene Therapy that Could Change the Course of Cancer

Genprex is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.

Read More

Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

Independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC).

Read More

Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company's presentation on September 9, 2019 in New York City.

Read More

Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck

These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found at Genprex.com.

Read More